Latest & greatest articles for fluoxetine

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on fluoxetine or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on fluoxetine and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for fluoxetine

41. Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria

Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Cost-effectiveness of mirtazapine compared to amitriptyline and fluoxetine in the treatment of moderate and severe depression in Austria Brown M C J, Nimmerrichter A A, Guest J F Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology The use of mirtazapine, amitriptyline, and fluoxetine in the treatment of moderate and severe depression in Austria. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Austrian people

NHS Economic Evaluation Database.1999

42. Acute medical costs of fluoxetine versus tricyclic antidepressants

Acute medical costs of fluoxetine versus tricyclic antidepressants Acute medical costs of fluoxetine versus tricyclic antidepressants Acute medical costs of fluoxetine versus tricyclic antidepressants Revicki D A, Palmer C S, Phillips S D, Reblando J A, Heiligenstein J H, Brent J, Kulig K Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed (...) by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Pharmaceutical: Tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs). Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Patients overdosing on either fluoxetine (SSRI) or tricyclic antidepressants (TCAs). Setting Hospital (emergency departments and intensive care/medical units). The economic study was carried out at 9

NHS Economic Evaluation Database.1997

43. A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression.

A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. 9099116 1997 04 30 1997 04 30 2013 11 21 0959-8138 314 7085 1997 Mar 29 BMJ (Clinical research ed.) BMJ A controlled study of fluoxetine and cognitive-behavioural counselling in the treatment of postnatal depression. 932-6 To study the effectiveness of fluoxetine and cognitive-behavioural counselling in depressive illness in postnatal women: to compare fluoxetine and placebo, six (...) sessions and one session of counselling, and combinations of drugs and counselling. Randomised, controlled treatment trial, double blind in relation to drug treatment, with four treatment cells: fluoxetine or placebo plus one or six sessions of counselling. 87 women satisfying criteria for depressive illness 6-8 weeks after childbirth, 61 (70%) of whom completed 12 weeks of treatment. Community based study in south Manchester. Psychiatric morbidity after 1, 4, and 12 weeks, measured as mean scores

BMJ1997 Full Text: Link to full Text with Trip Pro

44. Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment.

Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. 9174562 1997 06 17 1997 06 17 2015 06 16 0140-6736 349 9065 1997 May 31 Lancet (London, England) Lancet Randomised, double-blind, placebo-controlled trial of pindolol in combination with fluoxetine antidepressant treatment. 1594-7 Major depression affects more than 5% of the population and is a serious health and economic problem. Antidepressants have a slow onset of action (...) and are effective in less than two-thirds of patients. The biochemical effects of selective serotonin reuptake inhibitors may be limited by the negative feedback from serotonin autoreceptors. Pindolol is an antagonist of both serotonin autoreceptors and beta-adrenoceptors. We studied the effect of the addition of pindolol to fluoxetine antidepressant treatment. Of 132 eligible patients with major depression, 111 were randomly assigned to treatment with fluoxetine (20 mg daily) and either placebo or pindolol

Lancet1997

45. Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome.

Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. 8622391 1996 06 18 1996 06 18 2015 06 16 0140-6736 347 9005 1996 Mar 30 Lancet (London, England) Lancet Randomised, double-blind, placebo-controlled study of fluoxetine in chronic fatigue syndrome. 858-61 No somatic treatment has been found to be effective for chronic fatigue syndrome (CFS). Antidepressant therapy is commonly used. Fluoxetine is recommended in preference to tricyclic agents because (...) it has fewer sedative and autonomic nervous system effects. However, there have been no randomised, placebo-controlled, double-blind studies showing the effectiveness of antidepressant therapy in CFS. We have carried out such a study to assess the effect of fluoxetine in depressed and non-depressed CFS patients. In this randomised, double-blind study, we recruited 44 patients to the depressed CFS group, and 52 to the non-depressed CFS group. In each group participants were randomly assigned

Lancet1996

46. Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants.

Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. 8648870 1996 07 19 1996 07 19 2016 10 17 0098-7484 275 24 1996 Jun 26 JAMA JAMA Initial antidepressant choice in primary care. Effectiveness and cost of fluoxetine vs tricyclic antidepressants. 1897-902 To compare the clinical, functional, and economic outcomes of initially prescribing fluoxetine with outcomes of initially selecting imipramine or desipramine. Randomized controlled (...) trial. Primary care clinics of a Seattle, Wash, area staff-model health maintenance organization from 1992 through 1994. A total of 536 adults beginning antidepressant treatment for depression. Random assignment of initial antidepressant prescription (desipramine, fluoxetine, or imipramine). Subsequent antidepressant treatment (doses, medication changes or discontinuation, specialty referral) was managed by the primary care physician. Assessments after 1, 3, and 6 months examined clinical outcomes

JAMA1996

47. Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization

Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Antidepressant pharmacotherapy: economic evaluation of fluoxetine, paroxetine and sertraline in a health maintenance organization Sclar D A, Robison L M, Skaer T L, Galin R S, Legg R F, Nemec N L, Hughes T E, Buesching D P, Morgan M Record (...) Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Selective Serotonin Reuptake Inhibitors (SSRIs) in antidepressant pharmacotherapy; (a) paroxetine, (b)sertraline, and (c) fluoxetine in the treatment of depression. Type of intervention

NHS Economic Evaluation Database.1995

48. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group.

Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. 7739706 1995 06 08 1995 06 08 2013 11 21 0028-4793 332 23 1995 Jun 08 The New England journal of medicine N. Engl. J. Med. Fluoxetine in the treatment of premenstrual dysphoria. Canadian Fluoxetine/Premenstrual Dysphoria Collaborative Study Group. 1529-34 Premenstrual dysphoria shares certain features with depression and anxiety states, which have been linked (...) to serotonergic dysregulation. We evaluated the efficacy and safety of fluoxetine (which selectively inhibits the reuptake of serotonin) in the treatment of premenstrual dysphoria. The trial consisted of a single-blind, placebo washout period lasting two menstrual cycles, followed by a randomized, double-blind, placebo-controlled trial of fluoxetine at a dose of either 20 mg or 60 mg per day or placebo for six menstrual cycles. Healthy women meeting criteria for what was then called late-luteal-phase

NEJM1995

49. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy.

Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. 1560801 1992 05 08 1992 05 08 2013 11 21 0028-4793 326 19 1992 May 07 The New England journal of medicine N. Engl. J. Med. Effects of desipramine, amitriptyline, and fluoxetine on pain in diabetic neuropathy. 1250-6 Amitriptyline reduces the pain caused by peripheral-nerve disease, but treatment is often limited by side effects related to the drug's many pharmacologic actions. Selective agents might be safer (...) and more effective. We carried out two randomized, double-blind, crossover studies in patients with painful diabetic neuropathy, comparing amitriptyline with the relatively selective blocker of norepinephrine reuptake desipramine in 38 patients, and comparing the selective blocker of serotonin reuptake fluoxetine with placebo in 46 patients. Fifty-seven patients were randomly assigned to a study as well as to the order of treatment, permitting comparison among all three drugs and placebo as the first

NEJM1992